Some limitations of insulin delivery through pulmonary route are its expensiveness and that the bioavailability of insulin from pulmonary route is about 9%–22% of that of subcutaneous route, absorption of insulin is variable due to smoking, respiratory infections, and some age related factors, and insulin is required in large quantity as compared to other routes [81]. Here, INS is linked to respiratory tract infectious disorder.